We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Flow Cytometry-Based Method Analyzes Heinz Bodies

By LabMedica International staff writers
Posted on 26 Jan 2017
Heinz bodies are inclusions within red blood cells (RBCs) that are composed of denatured hemoglobin molecules and are a highly sensitive indicator of in vivo oxidative stress. More...
Heinz body formation has also been reported in chronic liver disease and α-thalassemia patient.

Historically, light microscopes have been used to visualize specially stained Heinz bodies, which can be seen as spherical inclusions at the peripheries of RBCs. However, microscopic examination of Heinz bodies is time-consuming, labor intensive, and of low sensitivity.

Scientists at the Chulalongkorn University and their associates collected whole-blood samples from patients deficient in Glucose-6-phosphate dehydrogenase (G6PD) and healthy volunteers. The study's G6PD-deficient group included patients who had previously been diagnosed. These subjects were apparently healthy and ranged in age from 25 to 45 and none had ever experienced an acute hemolytic crisis or had experienced fever, inflammation, or infection.

Washed RBCs were incubated in the acetylphenylhydrazine solution at 37 °C. After incubating for one hour, the Heinz bodies were counted under a light microscope at ×100. G6PD enzyme activity was determined using the G6PD assay kit. Enzyme activity was determined using a temperature-regulated spectrophotometer by measuring the change in rate in absorbance at 340 nm. RBCs positive for Heinz bodies were examined using a FACSCanto II cytometer.

The investigators found that RBCs treated with acetylphenylhydrazine formed Heinz bodies and emitted a broad spectrum of fluorescence that could be detected by flow cytometry. The maximum emission of fluorescence was observed at 45 minutes after the incubation with acetylphenylhydrazine. In addition, the fluorescence emitted was stable for at least 72 hours. The flow cytometer could detect the RBCs positive for Heinz bodies even if they made up as little as 0.1% of the total RBC population. Furthermore, the percentage and number, respectively, of RBCs positive for Heinz bodies in G6PD-deficient patients and normal donors exhibited a mean ± standard deviation (SD) of 68.9 ± 27.5 versus 50.9 ± 28.6 and 96,014 ± 35,732 cells/μL versus 74,688 ± 36,514 cells/μL.

The author concluded that Heinz bodies induced by acetylphenylhydrazine emit fluorescence, and this fluorescence could be examined using flow cytometry. Their study suggests the potential use of the developed method to investigate the formation of Heinz bodies in clinical samples. The study was published on January 16, 2017, in the International Journal of Laboratory Hematology.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.